ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 122 • 2023 Pediatric Rheumatology Symposium

    Juvenile Arthritis in Minnesota: Geospatial Variability and Environmental Exposures in Juvenile Idiopathic Arthritis

    Colleen Correll1, Austin Rau2 and Jesse Berman2, 1University of Minnesota, Minneapolis, MN, 2University of Minnesota, Minneapolis

    Background/Purpose: It is widely accepted that juvenile idiopathic arthritis (JIA) is caused by a combination of genetic and environmental factors, but the potential environmental triggers…
  • Abstract Number: 116 • 2023 Pediatric Rheumatology Symposium

    Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort

    Dawn Janysek1, Yiressy Pina2, Danielle Guffey3 and Marietta De Guzman1, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine, Houston, TX

    Background/Purpose: Production of autoantibodies is a hallmark of SLE, with ANAs as a required diagnostic feature and anti-dsDNA and anti-Smith antibodies being disease-specific. Anti-Scl-70 antibodies…
  • Abstract Number: 104 • 2023 Pediatric Rheumatology Symposium

    Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)

    Oscar Mwizerwa1, Andrea Knight2, Daniela Dominguez2, Deborah Levy2, Holly Convery2, Kendal Thompson2, Nicholas Gold2, Catharine Walsh2 and Linda Hiraki2, 1University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) and celiac disease (CD) are autoimmune diseases characterized by the presence of specific autoantibodies. We aimed to investigate the prevalence…
  • Abstract Number: 113 • 2023 Pediatric Rheumatology Symposium

    Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors

    Itay Marmor1, Rotem Semo Oz2, Amir hendel3, Guy Hazan4, Kevin Baszis5, Anthony French5, Cuoghi Edens6, Irit Tirosh7, Yonatan Butbul Aviel8, Liora Harel9 and Gil Amarilyo10, 1Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 2Sheba medical center, Herzelyia, Israel, 3Tel Aviv University, Tel Aviv, Israel, 4Soroka University Medical Center, Be'er Sheva, Israel, 5Washington University School of Medicine, St Louis, MO, 6University of Chicago, Chicago, IL, 7Sheba Medical Center, Savyon, Israel, 8Rambam Medical center, Haifa, Israel, 9Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, 10Schneider Children's Medical Center of Israel, Petach Tikva, Israel

    Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…
  • Abstract Number: 114 • 2023 Pediatric Rheumatology Symposium

    Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort

    Yiressy Pina1, Dawn Janysek1, Danielle Guffey2, Maria Pereira Palacios3 and Marietta De Guzman1, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Baylor College of Medicine, Houston, TX, 3Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Anti-nuclear antibodies (ANA) are important in the diagnosis of Systemic Lupus Erythematosus (SLE). Of the disease specific ANAs, anti-dsDNA and anti- Smith antibodies carry…
  • Abstract Number: 123 • 2023 Pediatric Rheumatology Symposium

    Development of Specific Classification Criteria for Juvenile System Sclerosis Patients: A Scoping Review

    Ioana Dobre1, Suzanne Li2, Natalia Vasquez Canizares3, Barbara Reich4, Xurong Zhao5, Quinn McCormick6 and Marinka Twilt5, 1Alberta Children's Hospital/University of Calgary, Calgary, AB, Canada, 2Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, 3Children's Hospital at Montefiore, New York, NY, 4Hackensack University Medical Center, Hackensack, NJ, 5Alberta Children's Hospital, Calgary, AB, Canada, 6Hackensack Medical Hospital Network, Hackensack, NJ

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is associated with one of the highest morbidity and mortality rate in pediatric rheumatology, yet care recommendations are based upon…
  • Abstract Number: 126 • 2023 Pediatric Rheumatology Symposium

    Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture

    Melanie Kohlheim1, Eveline Wu2, Laura Schanberg3, Vincent Del Gaizo1, Catherine Lavallee4, Marc Natter5, Katie Clem6, Brian Shakley6 and Kevin Urban7, 1CARRA, Washington, DC, 2UNC Chapel Hill, Chapel Hill, NC, 3Duke University Medical Center, Durham, NC, 4Virginia Tech Carilion School of Medicine, ROANOKE, VA, 5Boston Children's Hospital, Boston, MA, 6LIFT 1428, Llc, Ooltewah, TN, 7Business Coaching for Creatives, New York, NY

    Background/Purpose: The LIMIT-JIA trial aims to study if early abatacept treatment can prevent disease extension in children with recent-onset, uncomplicated, and oligoarticular or limited JIA.…
  • Abstract Number: 127 • 2023 Pediatric Rheumatology Symposium

    What’s in a Name? A20 Protein Expression in an in Vitro Model of A20 Haploinsufficiency

    Patricia Pontes Aires1, DANIELA GERENT PETRY PIOTTO1, Andre Cunha1, Sandro Perazzio2 and Maria Teresa Terreri3, 1Universidade Federal de São Paulo, São Paulo, Brazil, 2Universidade de So Paulo; Fleury Laboratories, São Paulo, Brazil, 3UNIFESP, São Paulo, Brazil

    Background/Purpose: Tumor necrosis factor alpha (TNF-alpha) induced protein 3 gene, or TNFAIP3, encodes the A20 protein, an important regulator of the NF-κB pathway. Since its…
  • Abstract Number: 101 • 2023 Pediatric Rheumatology Symposium

    Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity

    Susan Kim1, Rebecca Olveda2 and Jessica Neely2, 1UCSF Benioff Children's Hospital, San Francisco, CA, 2UCSF, San Francisco, CA

    Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…
  • Abstract Number: 131 • 2023 Pediatric Rheumatology Symposium

    Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative

    Jayne MacMahon1, Jeanine McColl2, Alaa Al-Shehab1, Deborah Levy3, Ronald laxer1 and Shirley Tse1, 1University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, 2University of Alberta, Edmonton, AB, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Prescribing methotrexate,is common practice in rheumatology. Appropriate medication counselling and documentation is important. In our province, as per thephysician regulatory body the College of…
  • Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium

    Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea

    Je Hee Shin1, Jung Yoon Pyo2, Minkyung Han3, Myeongjee Lee3, Sung Min Lim1, Jee Yeon Baek1, Ji Young Lee1, Ji-Man Kang1, InKyung Jung3 and Jong Gyun Ahn1, 1Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, 2Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, 3Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea

    Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…
  • Abstract Number: 133 • 2023 Pediatric Rheumatology Symposium

    An Interdisciplinary Team Approach to Implementation of a Social Determinants of Health Screener for Pediatric Rheumatology Patients

    Sarah Campbell1, Rosemary Peterson2, Sarah Barrientos3, Elinore Benett3 and Cori Christenholz3, 1University of Texas at Austin Dell Medical School, Austin, TX, 2Dell Medical School at UT Austin, Austin, TX, 3Dell Children's Medical Center Department of Rheumatology, Austin, TX

    Background/Purpose: Adolescents with chronic disease often struggle with the transition from pediatric to adult healthcare leading to poor follow-up and negative health outcomes. Social determinants…
  • Abstract Number: 130 • 2023 Pediatric Rheumatology Symposium

    Levels of Neutrophil Extracellular Traps Correlate with Disease Activity in Pediatric Lupus

    Lydia Thomas1, Jenna Battaglia2, Bharati Matta3, Kim Simpfendorfer4, Joyce Hui-Yuen5 and Betsy Barnes3, 1Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY, 2Northwell Health, New York, NY, 3Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, 4Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, 5Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY

    Background/Purpose: Pediatric lupus (pSLE) is a multisystemic autoimmune disease characterized by autoantibody production leading to organ damage. Neutrophil extracellular traps (NETs) are considered a potential…
  • Abstract Number: 129 • 2023 Pediatric Rheumatology Symposium

    Interrogation of STAT3 Activation in Patients with Polyarticular Juvenile Arthritis (polyJIA)

    Stephanie Wood1, Justin Branch1, Priscilla vasquez1, Marietta De Guzman1, Amanda Brown2, A. Carmela Sagcal-Gironella3, Saimun Singla4, Andrea Ramirez5 and Tiphanie Vogel5, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2University of Arkansas for Medical Sciences, Little Rock, AR, 3Hackensack University Medical Center, Hackensack, NJ, 4Self, Houston, TX, 5Baylor College of Medicine, Houston, TX

    Background/Purpose: A better understanding of the pathogenesis of polyJIA is necessary to guide more effective clinical care, such as the development of data-driven approaches to…
  • Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium

    Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis

    Alysha Taxter1, Marc Natter2, Min-Lee Chang2, Laura Schanberg3, Valarie Morrow4, Eveline Wu5, Tedryl Bumpass4, Alex Fist4, Meg Waite6, Vincent Del Gaizo7, Melanie Kohlheim7 and CARRA Registry Investigators7, 1Nationwide Children's Hospital, Columbus, OH, 2Boston Children's Hospital, Boston, MA, 3Duke University Medical Center, Durham, NC, 4Duke University, Durham, NC, 5UNC Chapel Hill, Chapel Hill, NC, 6Boston Children's Hospital, Boston, MA, 7CARRA, Washington, DC

    Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
  • « Previous Page
  • 1
  • …
  • 358
  • 359
  • 360
  • 361
  • 362
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology